<span item_type="fundamental" item_id="a2e3156556d267c74804f9a67662bfba" counter_id="ST/US/SLXNW" env="prod"></span><span item_type="announcement" item_id="515751467780477953" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD 0.26.</p><p>EBIT: As of FY2025 Q1, the actual value is USD -1.735 M.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Research and Development Expenses</strong>: $590,000 for the three months ended March 31, 2025, compared to $961,000 for the same period in 2024, representing a decrease of 40%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325001761/zk2533132.htm"></span></li><li><strong>General and Administrative Expenses</strong>: $1,060,000 for the three months ended March 31, 2025, compared to $289,000 for the same period in 2024, representing an increase of 266.7%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325001761/zk2533132.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: $1,735,000 for the three months ended March 31, 2025, compared to $1,423,000 for the same period in 2024, an increase of 21.4%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325001761/zk2533132.htm"></span></li><li><strong>Operating Loss</strong>: $1,650,000 for the three months ended March 31, 2025, compared to $1,250,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325001761/zk2533132.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: - $2,453,000 for the three months ended March 31, 2025, compared to - $1,752,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325001761/zk2533132.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: $7,432,000 for the three months ended March 31, 2025, compared to $0 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325001761/zk2533132.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Cash and Cash Equivalents</strong>: $6,233,000 as of March 31, 2025, compared to $2,831,000 as of March 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325001761/zk2533132.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to continue investing in the development of SIL204, including applying for Orphan Drug Designation in the U.S. and EU, conducting toxicological studies, and initiating clinical trials.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325001761/zk2533132.htm"></span></li><li><strong>Non-Core Business</strong>: The company is exploring additional product candidates to add to its pipeline and plans to expand its intellectual property portfolio.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325001761/zk2533132.htm"></span></li></ul>

SILEXION THERAPEUTICS CORP C/WTS EXP 15/08/2029 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD 0.26